Appointment dossier — Uterine Leiomyosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Uterine Leiomyosarcoma
- Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT07467772 · Phase 2 — Ph 2 Elacestrant in ER Positive Uterine Sarcomas (United States)
- NCT07076186 · Phase 2 — Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS (United States)
- NCT06524583 · Phase 2 — Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour (France)
- NCT05649956 · Phase 2 — Letrozole in Uterine Leiomyosarcoma (United States)
- NCT01793168 — Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (United States)
- NCT06172478 · Phase 2 — A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (United States)
- NCT06022757 · Phase 1 / Phase 2 — Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (China)
- NCT06330064 · Phase 2 — A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) (United States)
- NCT06781983 · Phase 1 — Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors (United States)
- NCT05103683 · Phase 1 — First in Human Study of TORL-1-23 in Participants With Advanced Cancer (United States)
- NCT06270706 · Phase 1 — A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors (United States)
- NCT07181720 · Phase 1 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors (China)
- NCT05979493 · Phase 4 — QL Block in Laparoscopic Myomectomy (United States)
- NCT05367206 · Phase 3 — Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial (China)
- NCT06641635 · Phase 3 — Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer (China)
- NCT06277154 · Phase 2 — MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (China)
- NCT07054567 · Phase 2 — A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer (China)
- NCT05080556 · Phase 2 — Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (United Kingdom)
Most-relevant first: trials that name Uterine Leiomyosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Trastuzumab Deruxtecan has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Trastuzumab-Deruxtecan (T-Dxd) has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT07467772), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?